CompletedNCT00130676
Mifepristone for psychotic depression
About this title
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Read the official source — NCT00130676Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Medication studyAges 18–75United States
Understand this study
What did researchers investigate?
Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Pico Rivera and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 257
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00130676
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Get this study by email
Recruitment & locations
CompletedPico Rivera · Riverside · San Diego
20 more locations
- Jacksonville
- Pompano Beach
- Atlanta
- Oak Brook
- Greenwood
- Farmington Hills
- Las Vegas
- Clementon
- Newark
- Toms River
- Glen Oaks
- Lawrence
- Dayton
- Lyndhurst
- Oklahoma City
- Philadelphia
- Bellaire
- Wichita Falls
- Richmond
- Bellevue
Questions about this study
What did researchers investigate?
Researchers compared Mifepristone and placebo, tracking side effects to assess safety in people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Mifepristone and matching placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
